Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemibotulinumtoxinA
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular Injection
01
Overview
gemibotulinumtoxinA (AGN-151607-DP) is an investigational drug developed by AbbVie. It is a botulinum toxin type A being studied for its safety and efficacy in facilitating primary fascial closure without the use of component separation technique in subjects undergoing open abdominal ventral hernia repair. The drug works by blocking the release of acetylcholine at the neuromuscular junction, leading to muscle relaxation.
- Other names
- gemibotulinumtoxinA-DP
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on gemibotulinumtoxinA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemibotulinumtoxinA.